Cargando…

CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease

Graves’ disease, an autoimmune disease with heterogeneous symptoms including Graves’ orbitopathy, has a combined genetic/environmental background, where variations within CD28/CTLA-4/ICOS genes are considered as disease markers. Association of CD28c.17+3T>C(rs3116496), CTLA-4g.319C>T(rs5742909...

Descripción completa

Detalles Bibliográficos
Autores principales: Pawlak-Adamska, Edyta, Frydecka, Irena, Bolanowski, Marek, Tomkiewicz, Anna, Jonkisz, Anna, Karabon, Lidia, Partyka, Anna, Nowak, Oskar, Szalinski, Marek, Daroszewski, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225215/
https://www.ncbi.nlm.nih.gov/pubmed/27638540
http://dx.doi.org/10.1007/s12020-016-1096-1
_version_ 1782493475942432768
author Pawlak-Adamska, Edyta
Frydecka, Irena
Bolanowski, Marek
Tomkiewicz, Anna
Jonkisz, Anna
Karabon, Lidia
Partyka, Anna
Nowak, Oskar
Szalinski, Marek
Daroszewski, Jacek
author_facet Pawlak-Adamska, Edyta
Frydecka, Irena
Bolanowski, Marek
Tomkiewicz, Anna
Jonkisz, Anna
Karabon, Lidia
Partyka, Anna
Nowak, Oskar
Szalinski, Marek
Daroszewski, Jacek
author_sort Pawlak-Adamska, Edyta
collection PubMed
description Graves’ disease, an autoimmune disease with heterogeneous symptoms including Graves’ orbitopathy, has a combined genetic/environmental background, where variations within CD28/CTLA-4/ICOS genes are considered as disease markers. Association of CD28c.17+3T>C(rs3116496), CTLA-4g.319C>T(rs5742909), CTLA-4c.49A>G(rs231775), CTLA-4g.*642AT(8_33), CT60(rs3087243), Jo31(rs11571302), ICOSc.1554+4GT(8_15) polymorphisms with susceptibility to Graves’ disease and clinical outcome was investigated. The study group comprised of 561 Polish Caucasians, including 172 unrelated Graves’ disease patients. CTLA-4c.49A>G, CTLA-4g.319C>T, and CT60 were genotyped by PCR–RFLP; Jo31 and CD28c.17+3C>T by minisequencing; CTLA-4g.*642AT(8_33) and ICOSc.1554+4GT(8_15)—PCR and fluorescence-based technique. CD28c.17+3T>C(rs3116496)T/CTLA-4g.319C>T(rs5742909)C/CTLA-4c.49A>G(rs231775)G/CTLA-4g.*642AT(8_33)(AT(16–21))/CT60(rs3087243)G/Jo31(rs11571302)G/ICOSc.1554+4GT(8_15)(m) and TCA(AT(<16))GT(m) haplotypes increased risk of Graves’ disease, especially in males, as well as overall Graves’ orbitopathy development with severe outcome. TCG(AT(16–21))GG(l) haplotype increased risk of Graves’ disease and reduced the chance of successful medical treatment. Although this haplotype was mainly observed in patients without signs of Graves’ orbitopathy, if Graves’ orbitopathy developed it favored a Graves’ orbitopathy outcome. Haplotype TCA(AT(>21))GT(m) increased Graves’ disease risk in women and, in all patients, was linked to Graves’ disease without Graves’ orbitopathy. TCG(AT(<16))GG(m) haplotype was predominantly observed in patients without Graves’ orbitopathy, whereas TCA(AT(16–21))GG(m) was absent in those patients. TCA(AT(16–21))GG(m) occurred in patients with a mild Graves’ orbitopathy outcome. The marker CTLA-4g.*642AT(8_33) was the only independent Graves’ disease risk factor, whereas CT60 was an independent factor for disease progression. Sporadic Graves’ disease was related to presence of CTLA-4c.49A>G[A] and the rare CTLA-4g.319C>T[T] allele variant. Familial background of the disease was exclusively associated with CTLA-4g.*642AT(8_33)[AT(>21)]/[AT(>21)] genotype. CD28/CTLA-4/ICOS loci may confer inherited susceptibility to Graves’ disease or may be involved in susceptibility to Graves’ disease and play a pathogenetic role.
format Online
Article
Text
id pubmed-5225215
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-52252152017-01-24 CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease Pawlak-Adamska, Edyta Frydecka, Irena Bolanowski, Marek Tomkiewicz, Anna Jonkisz, Anna Karabon, Lidia Partyka, Anna Nowak, Oskar Szalinski, Marek Daroszewski, Jacek Endocrine Original Article Graves’ disease, an autoimmune disease with heterogeneous symptoms including Graves’ orbitopathy, has a combined genetic/environmental background, where variations within CD28/CTLA-4/ICOS genes are considered as disease markers. Association of CD28c.17+3T>C(rs3116496), CTLA-4g.319C>T(rs5742909), CTLA-4c.49A>G(rs231775), CTLA-4g.*642AT(8_33), CT60(rs3087243), Jo31(rs11571302), ICOSc.1554+4GT(8_15) polymorphisms with susceptibility to Graves’ disease and clinical outcome was investigated. The study group comprised of 561 Polish Caucasians, including 172 unrelated Graves’ disease patients. CTLA-4c.49A>G, CTLA-4g.319C>T, and CT60 were genotyped by PCR–RFLP; Jo31 and CD28c.17+3C>T by minisequencing; CTLA-4g.*642AT(8_33) and ICOSc.1554+4GT(8_15)—PCR and fluorescence-based technique. CD28c.17+3T>C(rs3116496)T/CTLA-4g.319C>T(rs5742909)C/CTLA-4c.49A>G(rs231775)G/CTLA-4g.*642AT(8_33)(AT(16–21))/CT60(rs3087243)G/Jo31(rs11571302)G/ICOSc.1554+4GT(8_15)(m) and TCA(AT(<16))GT(m) haplotypes increased risk of Graves’ disease, especially in males, as well as overall Graves’ orbitopathy development with severe outcome. TCG(AT(16–21))GG(l) haplotype increased risk of Graves’ disease and reduced the chance of successful medical treatment. Although this haplotype was mainly observed in patients without signs of Graves’ orbitopathy, if Graves’ orbitopathy developed it favored a Graves’ orbitopathy outcome. Haplotype TCA(AT(>21))GT(m) increased Graves’ disease risk in women and, in all patients, was linked to Graves’ disease without Graves’ orbitopathy. TCG(AT(<16))GG(m) haplotype was predominantly observed in patients without Graves’ orbitopathy, whereas TCA(AT(16–21))GG(m) was absent in those patients. TCA(AT(16–21))GG(m) occurred in patients with a mild Graves’ orbitopathy outcome. The marker CTLA-4g.*642AT(8_33) was the only independent Graves’ disease risk factor, whereas CT60 was an independent factor for disease progression. Sporadic Graves’ disease was related to presence of CTLA-4c.49A>G[A] and the rare CTLA-4g.319C>T[T] allele variant. Familial background of the disease was exclusively associated with CTLA-4g.*642AT(8_33)[AT(>21)]/[AT(>21)] genotype. CD28/CTLA-4/ICOS loci may confer inherited susceptibility to Graves’ disease or may be involved in susceptibility to Graves’ disease and play a pathogenetic role. Springer US 2016-09-16 2017 /pmc/articles/PMC5225215/ /pubmed/27638540 http://dx.doi.org/10.1007/s12020-016-1096-1 Text en © The Author(s) 2016
spellingShingle Original Article
Pawlak-Adamska, Edyta
Frydecka, Irena
Bolanowski, Marek
Tomkiewicz, Anna
Jonkisz, Anna
Karabon, Lidia
Partyka, Anna
Nowak, Oskar
Szalinski, Marek
Daroszewski, Jacek
CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
title CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
title_full CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
title_fullStr CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
title_full_unstemmed CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
title_short CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
title_sort cd28/ctla-4/icos haplotypes confers susceptibility to graves’ disease and modulates clinical phenotype of disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225215/
https://www.ncbi.nlm.nih.gov/pubmed/27638540
http://dx.doi.org/10.1007/s12020-016-1096-1
work_keys_str_mv AT pawlakadamskaedyta cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease
AT frydeckairena cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease
AT bolanowskimarek cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease
AT tomkiewiczanna cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease
AT jonkiszanna cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease
AT karabonlidia cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease
AT partykaanna cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease
AT nowakoskar cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease
AT szalinskimarek cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease
AT daroszewskijacek cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease